Calcium supplementation and kidney stone risk in osteoporosis a systematic literature review
Table III. Main characteristics of the included studies.
Intervention Outcomes Quality*/comments
Study Population
Oxford 2b-c
Oxford 1c
Domrongkitchaiporn (14), 2002 RCT, 3 m follow-up
Vit D 800 UI/d Calcium suppl 1.000 mg/d Vit D 800 UI/d + calcium 1.000 mg/d Placebo Serum calcium Nephrolithiasis
Grant (15), 2005 double-blind placebo control RCT, 2 yr follow-up
Urinary calcium ALP Hidroxiproline excretion Nephrolithiasis
n=61 (n=31 calcium + oestrogen therapy, mean age: 54 yr; n=30 calcium, mean age: 66 yr) IC: PM women with OP EC: prior use of drugs affecting bone metabolism
n=5.292 (n=1.306 vit D + calcium suppl; n=1.343 vit D; n=1.311 calcium suppl; n=1.332 palcebo), mean age 77 yr, 85% women IC: ≥70 yr with OP fracture within 10 yr EC: bed or chair bound, cognitive impairment, cancer, renalstone, daily intake ≥200 IU vitamin D or ≥500 mg calcium supplements; intake in the past 5 years of bisphosphonates, calcitonin, hormonereplacement therapy
Calcium suppl 625 mg/d + conjugated equine oestrogen 0.625 mg/d and 5 mg medrogestone acetate/d from day 1 to 12 of each month Calcium 625 mg/d Urinary excretion of calcium, oxalate, citrate, phosphate Calcium/citrate ratio AP(CaOx) index Nephrolithiasis
Oxford 2b-c 29 dropouts (6 group 1; 8 group 2; 3 group 3; 12 group 4)
Hasling (16), 1994 RCT, 3 yr follow-up
Calcitonin 200 IU/d intranasal 1 m on-1 m off + vit D 0.25 μgr/d + calcium suppl 500 mg/d Vit D 0.25 μgr/d + calcium suppl 500 mg/d Urinary calcium ALP Ca/creatinine ratio Pyrilinks-D/creatinine ratio iPTH
n=74: cyclic oestrogen/progestogen therapy (group 1, n=20), calcium suppl (group 2, n=17), intermittent cyclic etidronate therapy (group 3, n=19), ADFR treatment with T3 as activator and etidronate as depressor (group 4, n=18) CI: PM women (52–75 yr) with spinal crush fracture OP CE: treatments that alter bone or calcium metabolism, alcohol abuse, thyroid disorders, abnormalities of renal or hepatic function prior treatment for OP Oestrogen + progestogen: 2 mg estradiol/1 mg estriol 1/d x 12 d é 2 mg estradiol/1 mg estriol /1 mg norethisteronacetate 1/d days 13-22 é 1mg estradiol/0.5 mg estriol 1/d from day 23 to 28 + calcium suppl 120 mg/d Calcium suppl 2.000 mg/d Etidronate 400 mg x 2 w é 13 w etidronate free (10 cycles) + calcium suppl 120 mg/d ADFR (cycles): 50 μgr T3 2/d x 1 w + etidronate 400 mg 2v/d x 2 w é 13 w etidronate free + calcium suppl 120 mg/d
Oxford 2a-b 11 dropouts (7 calcitonin group; 4 in vit D +calcium group)
958
iPTH 400 UI/d sc + vit D 400 UI/d + calcium dietary and suppl 1.500 mg/d Placebo
Hydrochlorothiazide 44 mg ± 9 mg/d Calcium suppl 1.100mg ± 251 mg/d + vit D 1.277 UI ± 685 IU/d
TPTD 20 μg/d sc + calcium suppl 1.000 mg/d + vit D 400–1.200 UI/d TPTD 40 μg/d sc + calcium suppl 1.000 mg/d + vit D 400–1.200 UI/d Placebo
Calcium suppl 1.000 mg/d (effervescent) Calcium suppl 1.000 mg/d (carbonate) Calcium suppl 1.200 mg/d (carbonate)
Calcium suppl 1.200 mg/d Placebo
Alendronate 5 mg/d
Kaskani (17), 2005 Open RCT, 1 yr follow-up n=102 (n=57 calcitonin + vit D + calcium suppl, mean age 59 yr; n=45 vit D + calcium suppl, mean age 58 yr) IC: PM women (51–70 yr) without any kind of medication that could affect bone metabolism for at least 6 m before EC: secondary OP, kidney or hepatic insuf ciency, cancer, hematological diseases, thyroid diseases, treatment with thyroxin, chronic diseases that affect bone metabolism
Oxford 1c
Urinary calcium Nephrolithiasis
Oxford 2b
Urinary calcium Neprholithiasis Oxford 1c 7 dropouts (4 women y 1 man in TPTD 20 μg group; 1 woman in TPTD 40 μg group, 2 women in the placebo group)
Urinary calcium Urinary hidroxiproline
Neprholithiasis
Oxford 3b
Legroux-Gerot (19) , 2004 Prospective study, 18 m follow-up
Kurland (18), 2000 double-blind placebo control RCT, 18 m follow-up
Need (21),1991 RCT, 3 d follow-up
Miller (20), 2007 2 parallel double-blind placebo-controlled RCT 1 yr follow-up
n=27 (n=14 hydrochlorothiazide, mean age 53 yr; n=13 calcium suppl + vit D, mean age 48 yr) IC: hypercalciuretic osteoporotic male patients
n=23 (n=10 iPTH + vit D + calcium, mean age 54 yr; n=13 placebo, mean age 49 yr) IC: men (30–60 yr) and idiopatic OP (z-score <-2.0 or a T-score <-2.5 at the lumbar spine or femoral neck) EC: OP drugs in the previous 6 m Urinary calcium Serum calcium 1-25 dihidroxivitamine D Osteocalcin Urinary N-telopéptido
Study 1: n=1.637 PM women, mean age 69 yr Study 2: n=437 men, mean age 58 yr IC: OP patients or patients with low bone mass EC: nephrolithiasis or urolithiasis, impaired hepatic or renal function, diseases or drugs that alter bone metabolism in the previous 2–24 m
Recker (22), 1996 double-blind placebo control RCT, 1 yr follw-up
n=35 women mean age 68 yr IC: hospitalised PM women with OP
Yasui (23), 2009 prospective cohort, 3 m follow-up n=12, mean age: 63 yr IC: PM women with OP and had stones comprised of calcium phosphate, calcium oxalate or both EC: prior treatments for OP, primary hyperparathyroidism, renal tubular acidosis or other metabolic conditions associated with urinary tract infections or renal failure
n=197 (n=94 prevalent fractures, mean age 75 yr; n=103 non prevalent fractures, mean age 72 yr) IC: women >60 yr living independently and consuming <1 g/day of calcium
Oxford 2c
Urinary calcium Urinary oxalate Urinary phosphate AP(CaP) index AP(CaOx) index Nephrolithiasis
Oxford 2b
RCT: randomised controlled trial; IC: inclusion criteria; EC: exclusion criteria; OP: osteoporosis; PM: postmenopausal; suppl: supplement; vit: vitamin; yr: year; m: moth; w: week; d: day; mg:milligram; μgr: microgram; Ca: calcium; AP(CaOx): ion activity product of calcium oxalate salts in urine; sc: subcutaneous; T3: triiodothyronine; ADFR: activate, depress, free, repeat; GC: glucocorticoids; ALP: alkaline phosphatase; iPTH: intact parathormone; PTH: parathormone; TPTD: teriparatide; BMD: bone mineral density; RA: rheumatoid arthritis.
Ian Reid and colleagues1 did a systematic review...calcium supplementation, baseline concentration of 25...risk in women with postmenopausal osteoporosis ...
Current status of research on osteoporosis in COPD: a systematic review L....interventions in osteoporosis, bisphosphonates, calcium supplementation, vitamin D...
calcium as part of the 191 osteoporosis management...Can vitamin D supplementation reduce the risk of ...falls in older persons: a systematic review. ...
osteoporosis, as well as systematic reviews and meta-analyses of previously ...Other data support the effectiveness of calcium and vitamin D supplementation ...
Calcium and Disease Prevention Osteoporosis ...levels actually reduces kidney stone formation risk... calcium supplementation may be necessary to obtain...
Osteoporosis: the role of micronutrients1– 4 ...Calcium supplementation and increases in bone ...older adults: a systematic review and meta-...
Calcium supplementation was used in 26 trials (6...Discussion We conducted a systematic review and ...patients with osteoporosis and fracture risk [84]...
Guided by systematic reviews of evidence in ... osteoporosis, chronic kidney disease, liver ...A daily supplementation of 1,000 IU of vitamin ...
? Osteoporosis Osteoporosis means “porous bone,”...levels actually reduces kidney stone formation risk... calcium supplementation may be necessary to obtain...
Data Sources: We conducted a systematic search in...health and preventing osteoporosis and falls (1, ...Calcium plus vitamin D supplementation and the ...
热门文档